Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found durable remission in Crohn’s, as patients with moderate-to-severe Crohn’s stayed in remission after 3 years of treatment. Moreover, data from VIVID-1 (Crohn’s) and LUCENT-3 ...